Novo Nordisk Withdraws More Insulin, this time from the UK market. As reported in the Herald Scotland,thousands of diabetic patients face changing medication as a pharmaceutical giant plans to withdraw a key treatment from the UK, creating extra work for the NHS at a time when hundreds of jobs are facing the axe.
This is the 2nd such announcement from Novo Nordisk stating that they are to withdraw insulin. The last announcement which is affecting Greece were for financial reasons, however it just feels plain wrong none the less.
Did they consult the end user of this product, the patient? Could they have consulted patients? What about medical professionals? Did anyone at Novo Nordisk actually stop to think about their actions, especially when they have critical ramifications.
Come on Novo Nordisk.. You guys need to get on the ball. Start communicating properly with patients and their care providers. If at the end of the day it has to be done, then make the process easier for the people that need to change insulin! But do it properly, please!!
In terms of Diabetes, Novo Nordisk is on a par with BP in terms of reputation, so you guys need to start working on this side of your game! What’s insulin is going to be next? Which country?
PS: For the record I use NovoRapid..
Wow! My experience with Novo Nordisk here in the USA has been the opposite of what you describe. Novo in the USA is very active in the Type 1 diabetes community. They sponsor numerous fund raising events for the Juvenile Diabetes Research Foundation and being very active in the community. It’s the very nature of the web site: http://www.novonordisk-us.com
Hi Khürt and thanks for stopping by.
I don’t doubt that Novo Nordisk work hard to interact with care providers and patient alike.
However one must remember that care provision is slightly different in the USA as it can really be classed as a full on Service industry.
In Europe many treatments are subsidised and/or free so at the end of the day “Big Pharma” does not have to deal with the patients as it will be the care providers that will be directed towards certain companies/brands/pharma companies.
Hope that helps explain the tough stance against Novo Nordisk.